Keywords
Abstract
In recent decades, there has been an active increase in the number of overweight and obese people all over the world, which makes this problem relevant for the medical community. According to some data, 8% of overweight women and 18% of obese women have problems with the exercise of reproductive function. Disorders of glucose, lipids, and arterial hypertension that often develop in patients with polycystic ovary syndrome (PCOS) allow it to be attributed to metabolic diseases. The complex of metabolic disorders, which are based on insulin resistance and hyperinsulinemia, is designated by the term "metabolic syndrome". PCOS can also be considered as one of its manifestations and is considered the most common cause of infertility in overweight and obese women. In the treatment of such patients, it is important to carry out complex therapy aimed not only at restoring reproductive function, but also at correcting metabolic disorders. Lifestyle correction, diet and regular physical activity are not widely used, and therefore there is a need to use and evaluate the effectiveness of pharmacological means of pregravidar preparation for weight loss and improvement of reproductive outcomes in patients with PCOS.